실제 임상에서 한국인 아토피피부염 환자를 대상으로 한 Upadacitinib 15 mg의 치료 효과 및 안전성에 대한 연구 (Real-World Experience of the Efficacy and Safety of Upadacitinib 15 mg in Patients with Atopic Dermatitis in Korea)

서지정보

· 발행기관 : 대한피부과학회
· 수록지 정보 : 대한피부과학회지 / 61권 / 2호 / 86 ~ 91페이지
· 저자명 : 나형민, 최은지, 전수현, 상중범, 최명은, 문익준, 정준민, 이우진, 장성은, 이미우, 원종현

초록

Background: Upadacitinib is an oral Janus kinase1 (JAK1)-selective inhibitor, which showed a quick and significanteffect on patients with atopic dermatitis in several phase 3 clinical studies. Although, an increasing number ofstudies have reported data on the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis,no studies have yet been published in Korea.
Objective: We assessed the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis inKorean patients.
Methods: A total of 17 patients with atopic dermatitis who received 15 mg of oral upadacitinib everyday for 16weeks, were included in this retrospective single-center study. Based on electronic medical records, the clinicalcharacteristics, Eczema Area and Severity Index (EASI) score, and adverse events were investigated.
Results: The mean EASI score was significantly reduced at 4 weeks of upadacitinib treatment (8.81±9.00) andgradually reduced at week 8 (5.70±7.38), week 12 (4.55±6.23), and week 16 (4.58±6.74) (p＜0.001). At week 16,61.54%, 30.77%, and 15.38% of patients achieved EASI 75, EASI 90, and EASI 100 responses, respectively. Therewas no statistically significant difference between EASI 75 and EASI 90 by age or gender at week 16 (p＞0.05).
A total of 13 people (76.5%) had adverse events, of which acne was the most common. In all patients, thesymptoms were mild and self-limited, and no patient discontinued treatment.
Conclusion: Upadacitinib was effective and safe for Korean patients with atopic dermatitis in real-world clinicalpractice.

영어초록

Background: Upadacitinib is an oral Janus kinase1 (JAK1)-selective inhibitor, which showed a quick and significanteffect on patients with atopic dermatitis in several phase 3 clinical studies. Although, an increasing number ofstudies have reported data on the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis,no studies have yet been published in Korea.
Objective: We assessed the real-world efficacy and safety of upadacitinib for the treatment of atopic dermatitis inKorean patients.
Methods: A total of 17 patients with atopic dermatitis who received 15 mg of oral upadacitinib everyday for 16weeks, were included in this retrospective single-center study. Based on electronic medical records, the clinicalcharacteristics, Eczema Area and Severity Index (EASI) score, and adverse events were investigated.
Results: The mean EASI score was significantly reduced at 4 weeks of upadacitinib treatment (8.81±9.00) andgradually reduced at week 8 (5.70±7.38), week 12 (4.55±6.23), and week 16 (4.58±6.74) (p＜0.001). At week 16,61.54%, 30.77%, and 15.38% of patients achieved EASI 75, EASI 90, and EASI 100 responses, respectively. Therewas no statistically significant difference between EASI 75 and EASI 90 by age or gender at week 16 (p＞0.05).
A total of 13 people (76.5%) had adverse events, of which acne was the most common. In all patients, thesymptoms were mild and self-limited, and no patient discontinued treatment.
Conclusion: Upadacitinib was effective and safe for Korean patients with atopic dermatitis in real-world clinicalpractice.

참고자료

· 없음